SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today ...

Holding announced the launch of Discover23, a new research offering enabling authorized collaborators to securely access the power ...

Genetic testing company 23andMe had a particularly rough year. The company went public via a SPAC in 2021, valuing the ...

Four out of 10 services (23andMe, SelfDecode ... to have exposed users' protected health information to Facebook and Google through tracing pixels. There is also the risk of data breaches and ...

23andMe, born from the techno-optimism of the Human Genome Project, revolutionized direct-to-consumer genetic testing. But with its valuation now in freefall, mounting layoffs and its board ...

23andMe, born from the techno-optimism of the Human Genome Project, revolutionized direct-to-consumer genetic testing. But with its valuation now in freefall, mounting layoffs and its board ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

23andMe, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In September 2024, the company's stock hit a rock-bottom of US$0.30, down 96 ...

23andMe, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In September 2024, the company’s stock hit a rock-bottom of US$0.30, down 96 per ...